LENZ Therapeutics, Inc. (LENZ) Tops Q2 EPS by 5c

LENZ Therapeutics, Inc. (NASDAQ: LENZ) reported Q2 EPS of ($1.02), $0.05 better than the analyst estimate of ($1.07). Revenue for the quarter came in at $5.5 million versus the consensus estimate of $2.49 million.

For earnings history and earnings-related data on LENZ Therapeutics, Inc. (LENZ) click here.

You May Also Be Interested In

• U.S. and Denmark close in on a Greenland deal - Reuters
• SmartKem (SMTK) files for 15.13M share offering by selling stockholders
• Leidos wins $85m Air Force contract for aerospace design